Lidocaine tetracaine cream — Competitive Intelligence Brief

Lidocaine tetracaine cream (Lidocaine tetracaine cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination. Area: Dermatology.

phase 3 Local anesthetic combination Voltage-gated sodium channels Dermatology Small molecule

Target snapshot

Lidocaine tetracaine cream (Lidocaine tetracaine cream) — Cutia Therapeutics（Wuxi）Co.,Ltd. Lidocaine and tetracaine are local anesthetics that block sodium channels in nerve cell membranes to inhibit pain signal transmission.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lidocaine tetracaine cream TARGET	Lidocaine tetracaine cream	Cutia Therapeutics（Wuxi）Co.,Ltd	phase 3	Local anesthetic combination	Voltage-gated sodium channels
Permethrin Cream, 5%	Permethrin Cream, 5%	Mayne Pharma International Pty Ltd	marketed	Synthetic pyrethroid insecticide	Voltage-gated sodium channels (arthropod nervous system)
Heavy Bupivacaine	Heavy Bupivacaine	Diskapi Yildirim Beyazit Education and Research Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Bupivacaine Spinal 0,5% Heavy - bolus	Bupivacaine Spinal 0,5% Heavy - bolus	Centre of Postgraduate Medical Education	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
prilocaine 1%	prilocaine 1%	Helios Research Center	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
All registered antiepileptic drugs	All registered antiepileptic drugs	UMC Utrecht	marketed	Antiepileptic drugs (heterogeneous class)	Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent
Standard dose oxcarbazepine	Standard dose oxcarbazepine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination class)

1. University of Belgrade · 2 drugs in this class
2. Cedars-Sinai Medical Center · 1 drug in this class
3. Cutia Therapeutics（Wuxi）Co.,Ltd · 1 drug in this class
4. East Carolina University · 1 drug in this class
5. Galderma R&D · 1 drug in this class
6. Hadassah Medical Organization · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of New Mexico · 1 drug in this class
9. Ain Shams University · 1 drug in this class
10. University of Wisconsin, Madison · 1 drug in this class